Intrinsic sensory deprivation induced by neonatal capsaicin treatment induces changes in rat brain and behaviour of possible relevance to schizophrenia.

Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print Cited Medium: Print ISSN: 0007-1188 (Print) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE

Publication: London : Wiley
Original Publication: London, Macmillian Journals Ltd.

Schizophrenia* ; Sensory Deprivation*; Behavior, Animal/*drug effects ; Brain/*drug effects ; Capsaicin/*pharmacology; Animals ; Animals, Newborn ; Brain/pathology ; Cell Count ; Female ; Male ; Neurons/cytology ; Neurons/drug effects ; Organ Size/drug effects ; Rats ; Rats, Wistar ; Sex Factors ; Tail/drug effects ; Tail/growth & development

Schizophrenia is considered to be a neurodevelopmental disorder with origins in the prenatal or neonatal period. Brains from subjects with schizophrenia have enlarged ventricles, reduced cortical thickness (CT) and increased neuronal density in the prefrontal cortex compared with those from normal subjects. Subjects with schizophrenia have reduced pain sensitivity and niacin skin flare responses, suggesting that capsaicin-sensitive primary afferent neurons might be abnormal in schizophrenia. This study tested the hypothesis that intrinsic somatosensory deprivation, induced by neonatal capsaicin treatment, causes changes in the brains of rats similar to those found in schizophrenia. Wistar rats were treated with capsaicin, 50 mg kg(-1) subcutaneously, or vehicle (control) at 24-36 h of life. At 5-7 weeks behavioural observations were made, and brains removed, fixed and sectioned. The mean body weight of capsaicin-treated rats was not significantly different from control, but the mean brain weight of male, but not female, rats, was significantly lower than control. Capsaicin-treated rats were hyperactive compared with controls. The hyperactivity was abolished by haloperidol. Coronal brain sections of capsaicin-treated rats had smaller cross-sectional areas, reduced CT, larger ventricles and aqueduct, smaller hippocampal area and reduced corpus callosum thickness, than brain sections from control rats. Neuronal density was increased in several cortical areas and the caudate putamen, but not in the visual cortex. It is concluded that neonatal capsaicin treatment of rats produces brain changes that are similar to those found in brains of subjects with schizophrenia.

Psychiatry Res. 2005 Jan 30;133(1):1-12. (PMID: 15698672)
J Neurosci Methods. 1985 May;13(3-4):305-11. (PMID: 2409409)
Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):162-8. (PMID: 15857679)
Neuropharmacology. 1988 Feb;27(2):135-42. (PMID: 3352871)
Pharmacol Rev. 1991 Jun;43(2):143-201. (PMID: 1852779)
N Engl J Med. 1992 Aug 27;327(9):604-12. (PMID: 1640954)
Am J Psychiatry. 1994 Jun;151(6):842-8. (PMID: 8184992)
Arch Gen Psychiatry. 1995 Oct;52(10):805-18; discussion 819-20. (PMID: 7575100)
Curr Opin Neurobiol. 1997 Apr;7(2):285-9. (PMID: 9142763)
Nature. 1997 Oct 23;389(6653):816-24. (PMID: 9349813)
J Comp Neurol. 1997 Oct 6;386(4):661-80. (PMID: 9378859)
Arch Gen Psychiatry. 1998 Mar;55(3):215-24. (PMID: 9510215)
J Comp Neurol. 1998 Mar 16;392(3):402-12. (PMID: 9511926)
Neuroreport. 1998 Jun 22;9(9):2045-8. (PMID: 9674591)
Biol Psychiatry. 1999 Jan 1;45(1):17-25. (PMID: 9894571)
Neuroimage. 1999 Jan;9(1):81-7. (PMID: 9918729)
Lancet. 1999 Apr 24;353(9162):1425-30. (PMID: 10227239)
Biol Psychiatry. 1999 May 1;45(9):1099-119. (PMID: 10331102)
Pharmacol Rev. 1999 Jun;51(2):159-212. (PMID: 10353985)
Schizophr Res. 2005 Feb 1;73(1):69-78. (PMID: 15567079)
Curr Med Chem. 2004 Dec;11(24):3185-202. (PMID: 15579007)
Prog Brain Res. 2005;147:319-45. (PMID: 15581715)
Schizophr Res. 1999 Nov 9;40(1):49-53. (PMID: 10541007)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3655-60. (PMID: 10725386)
Biol Psychiatry. 2000 Apr 1;47(7):681-3. (PMID: 10809534)
Reg Anesth Pain Med. 2000 Sep-Oct;25(5):475-9. (PMID: 11009232)
Neuron. 2000 Nov;28(2):325-34. (PMID: 11144342)
Schizophr Res. 2001 Mar 1;47(2-3):265-73. (PMID: 11278144)
Annu Rev Neurosci. 2001;24:487-517. (PMID: 11283319)
Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):691-707. (PMID: 11383973)
Neuropharmacology. 2001 Dec;41(8):1000-5. (PMID: 11747904)
J Nerv Ment Dis. 2002 Jul;190(7):481-3. (PMID: 12142852)
J Physiol. 2002 Sep 1;543(Pt 2):531-40. (PMID: 12205187)
Am J Med Genet. 2002 Aug 8;114(6):616-25. (PMID: 12210275)
Schizophr Res. 2002 Dec 1;58(2-3):173-83. (PMID: 12409156)
Am J Psychiatry. 2002 Dec;159(12):1983-91. (PMID: 12450946)
Learn Mem. 2002 Nov-Dec;9(6):430-42. (PMID: 12464703)
J Comp Neurol. 2003 Feb 24;457(1):75-86. (PMID: 12541326)
J Neurosci. 2003 Apr 15;23(8):3136-44. (PMID: 12716921)
Biol Psychiatry. 2003 Jun 15;53(12):1086-98. (PMID: 12814860)
Schizophr Res. 2003 Aug 1;62(3):251-8. (PMID: 12837522)
Arch Gen Psychiatry. 2003 Aug;60(8):766-75. (PMID: 12912760)
Am J Psychiatry. 2003 Dec;160(12):2148-53. (PMID: 14638585)
Eur J Neurosci. 2003 Dec;18(11):3097-104. (PMID: 14656305)
Int Rev Neurobiol. 2004;59:19-45. (PMID: 15006483)
Psychophysiology. 2004 May;41(3):361-6. (PMID: 15102120)
Biol Psychiatry. 2004 Jun 15;55(12):1128-37. (PMID: 15184031)
Biol Psychiatry. 2004 Oct 15;56(8):540-3. (PMID: 15476682)
Nature. 1977 Dec 22-29;270(5639):741-3. (PMID: 593396)
Neuropsychopharmacology. 2005 May;30(5):864-70. (PMID: 15562294)

S07O44R1ZM (Capsaicin)

Date Created: 20050726 Date Completed: 20060425 Latest Revision: 20181113

20221213

PMC1576292

10.1038/sj.bjp.0706349

16041396